Development of the MAbCancer data bank by Hybrizyme Corporation will allow interested investigators to immediately access the most current information available on monoclonal antibodies for use in the diagnosis and therapy of cancer. The data bank will be computerized, utilizing the tremendous data processing capability now found in virtually every office and laboratory.A prototype will be developed in Phase I containing information on representative monoclonal antibodies. In Phase II, the software and methodologies developed in Phase I will be used to establish and distribute a complete and regularly updated MAbCancer data bank to end users. Establishment and maintenance of the MAbCancer data bank will provide a unique bridge between basic and applied research that will facilitate the use of monoclonal antibodies in the treatment and diagnosis of cancer.
Anticipated Results:Successful commercialization of a database such as that envisioned in this project would be achieved by providing it as an on-going service, under contract, to agencies and institutions studying cancer.National Cancer Institute
